Middle-income countries in the Middle East and North Africa (MENA) are facing a difficult vaccine choice: the economic case for introducing key vaccines is increasingly strong, but the financing and delivery systems needed to act on that evidence remain uneven. A systematic review published in Vaccines assesses economic evaluations of pneumococcal conjugate vaccines, human papillomavirus vaccines and rotavirus vaccines across Algeria, Egypt, Iran, Jordan, Lebanon, Morocco, Palestine and Tunisia, covering studies published between 2015…
